# Qi Fu Capital

> Qi Fu Capital is a VC fund backing Machine Learning. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Taipei, Taiwan
- Total investments: 3
- Last investment: Jan 2026
- Lead investor: 67%
- Last updated: Aug 2026
- Website: https://nexuscvc.com

Qi Fu Capital is an investment management firm that focuses on investing in growth-stage startups.

## Contacts

5 contacts available for Qi Fu Capital. Shizune tracks 1 team members at Qi Fu Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/chi-fu-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Machine Learning | 2 | 67% |
| Artificial Intelligence | 2 | 67% |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 33% |
| Series F | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Taiwan | 1 | 33% |
| Singapore | 1 | 33% |
| United States | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| PC Chen | CEO & Managing Partner | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rakuten Medical | Rakuten Medical is a biotechnology company developing investigational cancer therapies based on its proprietary Alluminox platform. This platform integrates a drug, a device, and other components to deliver photoimmunotherapy, a treatment that combines a light-activated dye with a targeting agent to selectively destroy cancer cells. Thecompany's lead asset, ASP-1929, is an antibody-dye conjugate currently approved in Japan for treating unresectable locally advanced or recurrent head and neck cancer. Rakuten Medical is conducting global clinical trials to evaluate the safety and efficacy of its therapies in combination with other treatments. The company also offers an Expanded Access Program to provide investigational products to patients with serious or life-threatening diseases who lack other treatment options. Rakuten Medical operates in multiple countries and focuses on developing new cancer treatments based on its Alluminox™ platform. | $111.5M | Series F | Jan 07, 2026 |  |
| CloudMile | CloudMile, a leading AI and cloud technology company in Asia, focuses on digital transformation for its corporate clients and driving growth. Leveraging machine learning and big data analysis, CloudMile assists over 400 clients corporates with business forecasts and industrial upgrades. CloudMile has earned 120+ accreditations, with 60+ GoogleCloud professional certifications. Being the Premier Partner of Google Cloud, CloudMile is qualified for Machine Learning Specialization, Data Analytics Specialization, Cloud Migration Specialization and Infrastructure Specialization. In 2020, CloudMile becomes Taiwan's first Google Cloud Managed Service Provider (MSP) and the winner of Google Cloud Public Sector Partner of the Year in the APAC region. | $20M | Series C | Nov 04, 2025 |  |
| CyCraft | CyCraft secures national governments, Fortune 500 firms, and SMEs with our Japan Interop 2020 Best of Show and MITRE ATT&CK®-evaluated AI platform, CyCraft AIR, that delivers 1) endpoint detection & response, 2) network detection & response, 3) operational global threat intelligence and 4) enterprise cyber-health checks. | $4.5M | Venture - Series Unknown | May 28, 2025 |  |

3 of 3 investments shown.

## Co-investors
- Beike Star Venture Capital — VC Fund, 1 deal together
- [CID Group](https://shizune.co/investors/profile/cid-group) — VC Fund, 1 deal together
- [Daiwa Securities Group](https://shizune.co/investors/profile/daiwa-securities-group) — VC Fund, 1 deal together
- Guiding Star Venture Capital — VC Fund, 1 deal together
- [Mitsui Sumitomo Insurance Company](https://shizune.co/investors/profile/mitsui-sumitomo-insurance-company) — VC Fund, 1 deal together
- NCCU Star Venture Capital — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Qi Fu Capital invest in?

Qi Fu Capital invests primarily in Machine Learning, Artificial Intelligence and Medical startups, most often at Series C and Series F stage. Most of the 3 investments tracked by Shizune back companies in Taiwan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Qi Fu Capital?

Public channels for Qi Fu Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Qi Fu Capital?

The team at Qi Fu Capital includes PC Chen (CEO & Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co